Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT05732831RecruitingPhase 1/Phase 2
Study drug for tumors with MTAP loss
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
Palo Alto, CaliforniaAges 18 years+ - NCT05727904RecruitingPhase 3
New immunotherapy for advanced melanoma, with or without lifileucel
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Birmingham, AlabamaAges 18–70 - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT05720663Recruiting
Predicting liver outcomes in fatty liver cirrhosis
This study looks at how to predict future outcomes in adults who have fatty-liver disease (NAFLD) that has progressed to cirrhosis. It may help doctors better estimate risk and plan care, using information from liver tests and scans.
Rochester, MinnesotaAges 18 years+ - NCT05716516RecruitingPhase 2
Estradiol pill for ER-positive advanced breast cancer
This trial studies whether an estradiol (a form of estrogen) treatment can help people with ER-positive advanced breast cancer. It is mainly for post-menopausal women whose cancer is not curable and has already been treated with endocrine (hormone) therapies.
Lebanon, New HampshireAges 18 years+ - NCT05699018Recruiting
Screening people with liver scarring in primary care
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
AngersAges 40–80 - NCT05689853RecruitingPhase 1/Phase 2
Testing two targeted cancer drugs for advanced solid tumors
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
Beijing, Beijing MunicipalityAges 18–75 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Scottsdale, ArizonaAges 18 years+ - NCT02840019Recruiting
MRI scans during pregnancy to study baby and placenta development
This study uses advanced MRI pictures of the fetus (the baby) and placenta to better understand normal development and possible problems. You may qualify if you’re between 18 and 40 weeks pregnant and can have the MRI safely.
Boston, MassachusettsAges 18–45 - NCT05684094Recruiting
Study links sleep, stress, and brain reward in risky drinking
This study looks at how sleep timing and stress affect brain responses related to reward and stress in young adults who drink heavily. It may help researchers understand why some people take bigger alcohol risks and how sleep and stress could be part of safer treatment.
Eugene, OregonAges 18–24 - NCT05700721RecruitingPhase 2
Niraparib and dostarlimab for cancer with growing brain spots
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
Houston, TexasAges 18 years+ - NCT05679518Recruiting
Therapy to reduce fear of cancer progression
This study tests two types of talking therapy to help people who have recently been diagnosed with advanced cancer and feel strong fear about cancer getting worse. You may be able to join if you can speak Cantonese or Mandarin and can attend a set number of therapy sessions.
Hong KongAges 18 years+ - NCT05701176Recruiting
Imaging scan to see how anti–PD-1 changes lung cancer cells
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
AmsterdamAges 18 years+ - NCT04430452RecruitingPhase 2
Durvalumab with or without tremelimumab after liver radiation
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
San Francisco, CaliforniaAges 18 years+ - NCT05657405Recruiting
Study of data analytics for people with genetic conditions
This is an observational study that collects health and family history information to see how advanced data analysis can help people with genetic conditions. It may involve website forms, optional conversations, and sometimes an NIH visit, depending on your situation.
Bethesda, MarylandAges 1 day–120 years - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Daphne, AlabamaAges 18 years+ - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05657743Recruiting
Radiation seeds study for advanced pancreatic cancer safety
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
HolonAges 18 years+ - NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.